Tissue polypeptide specific antigen for early prediction of non-small cell lung cancer recurrence

Oncology Reports

Volumn 4, Issue 6, 1997, Pages 1391-1394

  Chen, Chih Yi ^a,b   Kao, Chia Hung ^a,c   Hsieh, Yung Hua ^a   Gu, Chiou Jeu ^a  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Non small cell lung cancers; Tissue polypeptide specific antigen

Indexed keywords

TISSUE POLYPEPTIDE ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ARTICLE; FEMALE; HUMAN; IMMUNORADIOMETRIC ASSAY; LUNG NON SMALL CELL CANCER; MALE; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENT CANCER;

EID: 0030959726     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.4.6.1391     Document Type: Article

References (14)

1. Stieber P, Dienemann H, Hasholzner U, et al: Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and tissue polypeptide specific antigen (TPS) as tumour markers in lung cancer. Eur J Clin Chem Clin Biochem 31: 689-694, 1993.
2. Nicolini A, Ferdeghini M and Colizzi C: Evaluation of CEA, TPA, CA 15-3, CA 549 and TPS in the monitoring of metastatic breast cancer. J Nucl Biol Med 37: 126-133, 1993.
3. Tarie M, Kovacic K and Kastelan M: Correlation of cell proliferation marker (TPS), natural killer (NK) activity and tumor load serotest (PSA) in untreated and treated prostatic tumors. Anticancer Res 13: 215-218, 1993.
4. Plebani M, Basso D, Del Favero G, et al: Clinical utility of TPS, TPA and CA 19-9 measurement in pancreatic cancer. Oncology 50: 436-440, 1993.
5. Spiro SG: Prognosis and end results. In: Lung Tumors. Hoogastraten B, Addis BJ, Hansen HH, Martini N and Spiro SG (eds). Springer-Verlag, Berlin, pp163-166, 1988.
6. O'Hanlon DM, Kerin MJ, O'Boyle C, Grimes H and Given H: Tissue polypeptide specific antigen (TPS) in breast cancer - an initial evaluation. Eur J Surg Oncol 22: 38-41, 1996.
7. Schuurman JJ, Bong SB and Einarsson R: Determination of serum tumor markers TPS and CA 15-3 during monitoring of treatment in metastatic breast cancer patients. Anticancer Res 16: 2169-2172, 1996.
8. Giai M, Roagna R, Ponzone R, Biglia N, Sgro L, Perona M and Sismondi P: TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients. Anticancer Res 16: 875-881, 1996.
9. Blijlevens NM, Oosterhuis WP, Oosten HR and Mulder NH: Clinical value of TPS, CEA and CA 15-3 in breast cancer patients. Anticancer Res 15: 2711 -2716, 1995.
10. Pujol JL, Grenier J, Parrat E, Lehmann M, Lafontaine T, Quantin X and Michel FB: Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS. Am J Respir Crit Care Med: 725-733, 1996.
11. Giovanella L, Ceriani L, Bandera M, Rimoldi R, Beghe B and Roncari G: Tissue polypeptide specific antigen (tps) and cytokeratin 19 fragment (CYFRA 21.1) immunoradiometric assay in non small cell lung cancer evaluation. Q J Nucl Med 39: 285-289, 1995.
12. Giovanella L, Ceriani L, Bandera M, Beghe B and Roncari G: Evaluation of the serum markers CEA, NSE, TPS and CYFRA 21.1 in lung cancer. Int J Biol Markers 10: 156-160, 1995.
13. Van der Gaast A, Schoenmakers CH, Kok TC, Blijenberg BG, Hop WC and Splinter TA: Prognostic significance of tissue polypeptide-specific antigen (TPS) in patients with advanced non-small cell lung cancer. Eur J Cancer 30A: 1783-1786, 1994.
14. Pujol JL, Cooper EH, Grenier J, Purves DA, Lehmann M, Ray P, Aouta MD, Bashir M, Godard P and Michel FB: Clinical evaluation of serum tissue polypeptide-specific antigen (TPS) in non-small cell lung cancer. Eur J Cancer 30A: 1768-1774, 1994.